암 생물학적 요법 시장 : 치료법별, 투여 경로별, 용도별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Cancer Biological Therapy Market is projected to grow by USD 347.87 billion at a CAGR of 7.45% by 2032.

Cancer Biological Therapy Market Introduction

Cancer biological therapy is reshaping oncology by using the immune system, engineered cells, antibodies, vaccines, cytokines, and targeted biologics to identify and destroy malignant cells with greater specificity than conventional chemotherapy. Demand is supported by the global cancer burden, with the International Agency for Research on Cancer reporting about 20 million new cancer cases and 9.7 million cancer deaths in 2022, and projecting new cancer cases to rise to more than 35 million by 2050.

Market momentum is strongest in immune checkpoint inhibitors, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, CAR-T cell therapies, cancer vaccines, oncolytic viruses, and next-generation cell and gene therapies. Adoption is increasingly tied to biomarker testing, companion diagnostics, real-world evidence, and reimbursement models that link clinical value to outcomes, including overall survival, durable response, safety, and patient quality of life.

Transformative Shifts in Cancer Biological Therapy

The cancer biological therapy landscape is moving from broad immunotherapy adoption toward precision immune modulation. PD-1, PD-L1, and CTLA-4 checkpoint inhibitors have established immuno-oncology as a standard component of care across melanoma, lung cancer, renal cell carcinoma, bladder cancer, head and neck cancer, gastrointestinal cancers, and several hematologic malignancies, while combination regimens are expanding treatment options.

At the same time, cell therapies, bispecific antibodies, antibody-drug conjugates, and tumor-agnostic biologic strategies are shifting competition toward differentiated mechanisms, manufacturing reliability, and patient selection. The market is also being transformed by subcutaneous formulations, outpatient administration, decentralized trials, biosimilar competition for mature biologics, and health technology assessment requirements that demand measurable survival, response, safety, and quality-of-life benefits.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across cancer biological therapy discovery, clinical development, manufacturing, and commercialization. AI-enabled platforms are used to identify tumor antigens, prioritize immune targets, model protein interactions, screen antibody candidates, optimize cell therapy constructs, and analyze multi-omics datasets that can improve biomarker-driven patient stratification.

In clinical practice and development, AI supports radiology, digital pathology, trial matching, toxicity monitoring, pharmacovigilance, and real-world evidence generation. Its impact is strongest when paired with validated datasets, transparent governance, and regulatory-grade documentation. For industry leaders, AI is not a standalone replacement for biological validation; it is an accelerator that can reduce cycle time, improve trial design, strengthen manufacturing analytics, and support safety monitoring for complex oncology biologics.

Regional Insights Across Cancer Biological Therapy

North America remains a leading region for cancer biological therapy innovation, supported by FDA oncology approvals, high biomarker testing adoption, major academic cancer centers, and strong venture and biopharmaceutical investment. The United States anchors clinical trial activity and early adoption of immuno-oncology, cell therapy, bispecific antibodies, and antibody-drug conjugates, while Canada supports evidence-based access through provincial reimbursement systems, oncology networks, and national cancer control initiatives.

Europe is shaped by EMA regulation, national health technology assessment, pharmacovigilance standards, and strong research infrastructure across the European Union, the United Kingdom, Germany, France, Italy, and Spain. Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, and Australia increase domestic biologics capacity, oncology trials, biosimilar production, genomic testing, and cell therapy research. Latin America, led by Brazil and Mexico, is improving oncology access through public and private care channels but still faces reimbursement, diagnostic, and infrastructure gaps. The Middle East, especially GCC markets, is investing in specialty care, oncology centers, genomic medicine, and precision oncology hubs, while Africa remains focused on earlier diagnosis, pathology capacity, trained workforce, cold-chain infrastructure, and equitable biologics availability.

Group Insights Shaping Market Access

The European Union supports cancer biological therapy through centralized regulatory pathways, cross-border research programs, pharmacovigilance standards, rare disease and advanced therapy frameworks, and increasing use of joint clinical assessment. G7 markets remain central to oncology R&D, premium biologics launches, intellectual property creation, clinical guideline development, and payer frameworks that evaluate overall survival, progression-free survival, safety, patient-reported outcomes, and comparative value.

BRICS countries are becoming more influential through larger patient populations, expanding domestic manufacturing, biosimilar development, public health investment, and growing clinical trial participation, particularly in China, India, and Brazil. ASEAN markets are strengthening regulatory cooperation, hospital oncology capacity, and access to biosimilars, though availability varies widely by income level, specialist workforce, and reimbursement maturity. GCC countries are using national cancer strategies, procurement scale, digital health investment, and tertiary care expansion to accelerate adoption. NATO members are relevant to supply-chain resilience, cybersecurity, emergency preparedness, and continuity planning for high-value biologics, advanced therapies, and cold-chain medicines.

Country Insights for Cancer Biological Therapy

The United States leads cancer biological therapy commercialization through FDA expedited pathways, extensive oncology networks, biomarker testing infrastructure, and strong uptake of immuno-oncology, CAR-T cell therapy, bispecific antibodies, and antibody-drug conjugates. Canada emphasizes evidence-based reimbursement and coordinated cancer care, while Mexico and Brazil represent major Latin American opportunities where private-sector adoption is often faster than public access. The United Kingdom combines MHRA oversight, NICE assessment, the Cancer Drugs Fund, and genomic medicine initiatives, while Germany and France remain major European launch markets with advanced oncology infrastructure, early access mechanisms, and strong clinical research activity.

Italy and Spain show strong clinical adoption within national health systems, supported by specialist oncology centers and participation in multinational trials, while Russia has focused on local biologics production amid changing trade and regulatory conditions. China is rapidly advancing domestic PD-1 inhibitors, antibody platforms, biosimilars, and cell therapy pipelines. India is expanding biosimilars, clinical research capacity, and cost-sensitive oncology access. Japan maintains high regulatory quality, universal healthcare coverage, and early innovation adoption, South Korea is a strong biologics manufacturing and clinical research hub, and Australia supports oncology trials through high-quality care networks, precision medicine programs, and regulatory alignment with global standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development, companion diagnostic integration, and adaptive trial designs that identify responders earlier and improve evidence quality. Competitive advantage will increasingly depend on proving differentiated survival benefit, manageable toxicity, durable response, feasible administration, and patient-relevant outcomes in real-world oncology settings.

Organizations should invest in scalable biologics manufacturing, cold-chain reliability, cell therapy logistics, release testing, and quality systems that meet global regulatory expectations. Market access teams should build evidence packages for payers early, including comparative effectiveness, health economics, budget impact logic without unsupported forecasts, and real-world outcomes. Partnerships with academic cancer centers, diagnostics developers, AI specialists, contract manufacturers, and regional production networks can accelerate development while improving affordability, geographic reach, and continuity of supply.

Research Methodology

This executive summary is based on secondary research and market intelligence synthesis from authoritative oncology, regulatory, clinical, and public health sources. Inputs include global cancer burden data from IARC and WHO, regulatory information from agencies such as FDA and EMA, clinical development trends from oncology trial registries, and peer-reviewed evidence on immunotherapy, cell therapy, antibodies, antibody-drug conjugates, vaccines, and biomarker-guided treatment.

The methodology emphasizes triangulation across disease burden, approval activity, therapeutic class evolution, regional access dynamics, reimbursement patterns, manufacturing capacity, diagnostic readiness, and technology adoption. Insights were reviewed for consistency, commercial relevance, and applicability to the cancer biological therapy market, with preference given to verified public data, established clinical evidence, regulatory publications, and recognized oncology practice guidelines.

Conclusion: Future of Cancer Biological Therapy

Cancer biological therapy is entering a more selective, data-driven, and outcomes-focused phase. Immuno-oncology has become a foundation of modern cancer care, while bispecific antibodies, cell therapies, antibody-drug conjugates, cancer vaccines, oncolytic viruses, and engineered immune platforms are broadening the treatment landscape.

Future progress will depend on better biomarkers, scalable manufacturing, AI-enabled development, payer-ready evidence, and equitable access across mature and emerging markets. Organizations that combine scientific differentiation with operational execution, regulatory discipline, supply-chain resilience, and patient-centered value will be best positioned to lead the next wave of oncology biologics innovation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Biological Therapy Market, by Therapy Type

• 7.1. Cancer Vaccines
• 7.2. CAR T-Cell Therapy
• 7.3. Cytokine Therapy
• 7.4. Gene Therapy
• 7.5. Monoclonal Antibodies
  • 7.5.1. Chimeric
  • 7.5.2. Human
  • 7.5.3. Murine
• 7.6. Oncolytic Viral Therapy

8. Cancer Biological Therapy Market, by Administration Route

• 8.1. Intramuscular
• 8.2. Intravenous
• 8.3. Oral
• 8.4. Subcutaneous

9. Cancer Biological Therapy Market, by Application

• 9.1. Breast Cancer
• 9.2. Colorectal Cancer
• 9.3. Hematologic Malignancies
• 9.4. Melanoma
• 9.5. Non-Small Cell Lung Cancer
• 9.6. Prostate Cancer

10. Cancer Biological Therapy Market, by End User

• 10.1. Ambulatory Care Centers
• 10.2. Home Healthcare
• 10.3. Hospitals
• 10.4. Research Laboratories
• 10.5. Specialty Clinics

11. Cancer Biological Therapy Market, by Distribution Channel

• 11.1. Offline
• 11.2. Online

12. Cancer Biological Therapy Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Cancer Biological Therapy Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Cancer Biological Therapy Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc.
• 16.2. Amgen Inc.
• 16.3. Astellas Pharma Inc.
• 16.4. AstraZeneca PLC
• 16.5. Autolus Therapeutics plc
• 16.6. Bayer AG
• 16.7. BeiGene, Ltd.
• 16.8. BioNTech SE
• 16.9. Bristol-Myers Squibb Company
• 16.10. C4 Therapeutics, Inc.
• 16.11. CRISPR Therapeutics AG
• 16.12. Daiichi Sankyo Company, Limited
• 16.13. Eli Lilly and Company
• 16.14. F. Hoffmann-La Roche Ltd
• 16.15. Gilead Sciences, Inc.
• 16.16. GSK plc
• 16.17. Incyte Corporation
• 16.18. Iovance Biotherapeutics, Inc.
• 16.19. Jazz Pharmaceuticals plc
• 16.20. Johnson & Johnson
• 16.21. Legend Biotech Corporation
• 16.22. MacroGenics, Inc.
• 16.23. Merck & Co., Inc.
• 16.24. Moderna, Inc.
• 16.25. Novartis AG
• 16.26. Pfizer Inc.
• 16.27. Regeneron Pharmaceuticals, Inc.
• 16.28. Seagen Inc.
• 16.29. Takeda Pharmaceutical Company Limited